195 related articles for article (PubMed ID: 33742733)
1. Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients.
McEneny-King A; Chelle P; Goggans MH; Barker PJ; Jacobs TW; Neufeld EJ; Reiss UM; Panetta JC
Haemophilia; 2021 May; 27(3):408-416. PubMed ID: 33742733
[TBL] [Abstract][Full Text] [Related]
2. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
Yu JK; Iorio A; Edginton AN
Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
[TBL] [Abstract][Full Text] [Related]
4. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
[TBL] [Abstract][Full Text] [Related]
5. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
[TBL] [Abstract][Full Text] [Related]
6. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
7. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
9. Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?
Goedhart TMHJ; Bukkems LH; van Moort I; Spence CC; Zwaan MC; de Maat MPM; Mathôt RAA; Cnossen MH;
Haemophilia; 2022 Jul; 28(4):610-618. PubMed ID: 35526235
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176
[TBL] [Abstract][Full Text] [Related]
11. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
Delavenne X; Dargaud Y; Ollier E; Négrier C
Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
[TBL] [Abstract][Full Text] [Related]
12. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
[TBL] [Abstract][Full Text] [Related]
13. A personalized limited sampling approach to better estimate terminal half-life of FVIII concentrates.
Chelle P; Iorio A; Edginton AN
J Thromb Haemost; 2022 Sep; 20(9):2012-2021. PubMed ID: 35753074
[TBL] [Abstract][Full Text] [Related]
14. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
Astermark J; Olsson A; Chelle P; Täckström K; Walger M; Magnusson M; Iorio A
Haemophilia; 2021 Jul; 27(4):626-633. PubMed ID: 33966319
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of extended half-life factor VIII in children with severe haemophilia A.
Dettoraki A; Michalopoulou A; Mazarakis M; Saslis S; Stamati I; Kapsimali Z; Pergantou H
Haemophilia; 2022 Jul; 28(4):619-624. PubMed ID: 35503081
[TBL] [Abstract][Full Text] [Related]
16. Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.
Bukkems LH; Valke LLFG; Barteling W; Laros-van Gorkom BAP; Blijlevens NMA; Cnossen MH; van Heerde WL; Schols SEM; Mathôt RAA
Br J Clin Pharmacol; 2022 Jun; 88(6):2757-2768. PubMed ID: 34921439
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
Björkman S; Folkesson A; Jönsson S
Eur J Clin Pharmacol; 2009 Oct; 65(10):989-98. PubMed ID: 19557401
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of children with haemophilia A receiving low-dose FVIII prophylaxis in Indonesia: A single centre experience.
Primacakti F; Sari TT; Gatot D; Sjakti HA; Chozie NA
Haemophilia; 2022 Sep; 28(5):720-725. PubMed ID: 35537097
[TBL] [Abstract][Full Text] [Related]
19. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
Turecek PL; Johnsen JM; Pipe SW; O'Donnell JS;
Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
Katragadda S; Neelakantan S; Diao L; Wong N
J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
